- Home
- NOG vs SRPT Comparison
NOG vs SRPT Comparison
Compare NOG & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NOG | SRPT |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2000 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NOG | SRPT |
|---|---|---|
| Price | $26.97 | $21.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 29 |
| Target Price | ★ $31.57 | $25.85 |
| AVG Volume (30 Days) | 2.6M | ★ 3.2M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,475,723,000.00 | $2,198,237,000.00 |
| Revenue This Year | $11.83 | N/A |
| Revenue Next Year | $3.32 | N/A |
| P/E Ratio | $69.53 | ★ N/A |
| Revenue Growth | 11.23 | ★ 15.58 |
| 52 Week Low | $20.18 | $10.42 |
| 52 Week High | $32.62 | $64.80 |
Technical Indicators
Market Signals| Indicator | NOG | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 55.46 |
| Support Level | $26.58 | $20.61 |
| Resistance Level | $28.90 | $23.51 |
| Average True Range (ATR) | 1.11 | 1.49 |
| MACD | -0.34 | 0.16 |
| Stochastic Oscillator | 11.65 | 64.90 |
Price Performance
Historical ComparisonAbout NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.